Breathing Support After Breathing Tube Removal in Severely Obese Patients
Tests noninvasive breathing support after tube removal in adults with severe obesity.
Plain-language title generated from the registry record
Registry title: Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients
Key facts
- Where
- Guadalajara, MexicoSee the site
Where in Mexico
- Hospital Civil Fray Antonio AlcaldeGuadalajara, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rush University Medical Center
- Trial code
- NCT05918575
- Record updated
- 7 August 2026
- Original description
Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube again.Read full original descriptionShow less
A Randomized Controlled Trial of Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients
Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube again.
Inclusion: Adult, age ≥ 18 years old; Receiving invasive mechanical ventilation for ≥24 hours; BMI ≥40 kg/m2; Undergoing planned extubation per treating team; Arterial pH ≥7.35 or venous pH ≥ 7.31 within 30 mins of spontaneous breathing trial (SBT).
Exclusion: Underlying neuromuscular disease; Documented/known history of chronic hypercapnic respiratory failure on home NIV (including bilevel PAP); Pregnant; Use of extra-corporeal membrane oxygenation; Chronic tracheostomy in place; Unplanned or accidental extubation; Terminal/compassionate extubation; Contraindication to NIV use; Intubated because of an acute exacerbation of COPD; No reintubation requested by patient/family; Enrolled in any other outcome study; Treating clinician feels that HFNC or NIV are either mandatory or contraindicated for a given patient.